“The highest levels of NIH are very concerned,” said Dr. Avindra Nath, intramural clinical director and a leader of viral research at the National Institute for Neurological Disorders and Stroke, an NIH division. “Everyone’s hopes are on a vaccine, and if you have a major complication the whole thing could get derailed.” A great deal… Read More »
By ANISH KOKA A recent email that arrived in my in-box a few weeks ago from an academic hailed the latest “paradigm shift” in cardiology as it relates to the management of stable angina. (Stable angina refers to chronic,non-accelerating chest pain with a moderate level of exertion). The points made in the email were as… Read More »
WEDNESDAY, Sept. 9, 2020 — Researchers may have found a way for people with severe hemophilia to take their standard treatment less often, if the results of an early trial pan out. In what experts called a feat of bioengineering, scientists were able to create a “fusion protein” that may extend the interval between treatments… Read More »
AstraZeneca put the rest of the SGLT2 inhibitor class on notice when its Farxiga scored an FDA heart failure nod in patients with or without diabetes. One of its competitors, Eli Lilly and Boehringer Ingelheim’s Jardiance, is fast on Farxiga’s heels, though, and it’s ready to bring its pivotal trial win in front of physicians. Jardiance, added… Read More »